£42.00 (exc VAT)
£50.40 (inc VAT)
White-yellowish suspension for injection.
Composition per dose (2 ml): F4ab fimbrial adhesin of E. coli ≥65% ER60 *, F4ac fimbrial adhesin of E. coli ≥78% ER70, F5 fimbrial adhesin of E. coli ≥79% ER50, F6 fimbrial adhesin of E. coli ≥80% ER25, LT Enterotoxoid of E. coli ≥55% ER70, Toxoid Clostridium perfringens, type C ≥35% ER25, Toxoid Clostridium novyi ≥50% ER120.
*% ERx: Percentage of immunized rabbits with a X serological EIA response
Adjuvants: Aluminium hydroxide gel 0.5 g, Ginseng extract (equivalent to ginsenosides) 4 mg (0.8 mg)
Excipient: Benzyl alcohol 30 mg
Piglets: For the passive protection of neonatal piglets by means of the active immunisation of breeding sows and gilts to reduce mortality and clinical signs of neonatal enterotoxicosis, such as diarrhoea caused by enterotoxigenic Escherichia coli, which express F4ab (K88ab), F4ac (K88ac), F5 (K99) or F6 (987P) adhesins.
The persistence of these antibodies has not been established.
For the passive immunisation of neonatal piglets against Necrotic Enteritis by means of the active immunisation of breeding sows and gilts to induce seroneutralizing antibodies against the β-toxin of Clostridium perfringens type C.
The persistance of antibodies has not been established
Sows and gilts: For active immunisation of breeding sows and gilts to induce seroneutralizing antibodies against α-toxin of Clostridium novyi. The relevance of the seroneutralizing antibodies was not experimentally determined.
Antibodies have been detected 3 weeks after vaccinaton. The persistence of these antibodies has not been established.
Legal Category: POM-V
Swine: 2 ml/animal intramuscular.
The basic vaccination scheme consists of two doses: the first dose at approximately 6 weeks before farrowing and a second dose at approximately 3 weeks before farrowing.
It is recommended that the second dose should be given preferably on alternate sides.
Re-vaccination: on each subsequent gestation, administer one dose 3 weeks before the expected date of farrowing.
It is advisable to administer the vaccine at a temperature between +15ºC and +25ºC. Shake before use.
Withdrawal Period: Zero days
Only healthy animals should be vaccinated.
Hypersensitivity reactions may occur in sensitive animals. In the event of an anaphylactic reaction appropriate treatment such as adrenaline should be administered without delay.
A small granuloma may occur in the muscle tissue at the injection site. The administration of the vaccine can cause the appearance of a small (less than 3 cm), local, transitory swelling (for 24-48 hours). In a few cases (up to 1% of the animals), temporary small nodules can be observed, which disappear within 2-3 weeks. The vaccination may cause a slight increase in body temperature for a transient period after vaccination (4-6 hours after injection). Rarely, an increase in rectal temperature higher than 1.5ºC, lasting less than 6 hours, may occur.
Can be used during pregnancy from 6 weeks before the expected farrowing date.
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
For the most up to date information about this product please look up the Summary of Product Characteristics (SPC) on the VMD webpage Product Information Database.